DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29^th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A.

The conference call with management will follow the release of the Company’s fourth quarter and full year 2023 financial results in the pre-market hours.  

To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow retail and institutional shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call. 

Starting on February 15^th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting:  https://app.saytechnologies.com/amarin-2023-q4.This Q&A platform will remain open until 24 hours before the start of the earnings call. Shareholders can email This email address is being protected from spambots. You need JavaScript enabled to view it. for any support inquiries.

Conference Call and Webcast Information: 
 
Access to the live call: 
Go to the investor relations section of the Company's website at www.amarincorp.com 
Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 996476

Access to replay: 
Dial in within the United States: 877-481-4010 
International dial in: 919-882-2331  
Access Code: 49775
 
A replay of the call will also be available through the Company's website shortly after the call. 

About Amarin   

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.   

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information   
Investor Inquiries:   
Amarin Corporation plc   
This email address is being protected from spambots. You need JavaScript enabled to view it. (investor inquiries)  
  
Media Inquiries:  
Amarin Corporation plc   
This email address is being protected from spambots. You need JavaScript enabled to view it. (media inquiries)